Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)

Fei Li, Shou-Ching Tang

Research output: Contribution to journalEditorial

6 Citations (Scopus)

Abstract

We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalGenes and Diseases
Volume4
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Paclitaxel
Blood-Brain Barrier
Brain
Breast Neoplasms
Phase II Clinical Trials
Peptides
Brain Neoplasms
Interviews
paclitaxel-Angiopep-2 conjugate

Keywords

  • ANG1005
  • Brain metastasis
  • Breast cancer
  • LRP-1
  • The blood-brain-barrier

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics(clinical)
  • Cell Biology

Cite this

Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB). / Li, Fei; Tang, Shou-Ching.

In: Genes and Diseases, Vol. 4, No. 1, 01.03.2017, p. 1-3.

Research output: Contribution to journalEditorial

@article{a87eebf3abab431f825a570e04505f75,
title = "Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)",
abstract = "We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.",
keywords = "ANG1005, Brain metastasis, Breast cancer, LRP-1, The blood-brain-barrier",
author = "Fei Li and Shou-Ching Tang",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.gendis.2017.01.004",
language = "English (US)",
volume = "4",
pages = "1--3",
journal = "Genes and Diseases",
issn = "2352-3042",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)

AU - Li, Fei

AU - Tang, Shou-Ching

PY - 2017/3/1

Y1 - 2017/3/1

N2 - We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.

AB - We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.

KW - ANG1005

KW - Brain metastasis

KW - Breast cancer

KW - LRP-1

KW - The blood-brain-barrier

UR - http://www.scopus.com/inward/record.url?scp=85015654049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015654049&partnerID=8YFLogxK

U2 - 10.1016/j.gendis.2017.01.004

DO - 10.1016/j.gendis.2017.01.004

M3 - Editorial

AN - SCOPUS:85015654049

VL - 4

SP - 1

EP - 3

JO - Genes and Diseases

JF - Genes and Diseases

SN - 2352-3042

IS - 1

ER -